查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1706786

PD-1抑制劑藥物市場－全球產業分析、規模、佔有率、成長、趨勢及預測（2025-2035）

PD-1 Inhibitor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
出版日期: | 出版商: Transparency Market Research | 英文 242 Pages | 商品交期: 2-10個工作天內

價格

PD-1抑制劑藥物市場-報告範圍

TMR 關於全球 PD-1 抑制劑藥物市場的報告研究了過去和當前的成長趨勢和機會，以獲得 2025 年至 2035 年預測期內市場指標的寶貴見解。該報告提供了 2019 年至 2035 年期間全球 PD-1 抑制劑藥物市場的收入，以 2025 年為基準年，2035 年為預測年。報告中也提供了2025年至2035年全球PD-1抑制劑藥物市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初步研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了訪談。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解 PD-1 抑制劑藥物市場。

市場概況
2024 年的市場價值 414億美元
2035年的市場價值 2015億美元
複合年成長率 15.5%

該報告深入探討了全球 PD-1 抑制劑藥物市場的競爭格局。已經確定了全球 PD-1 抑制劑藥物市場的主要參與者，並根據各種屬性對每個參與者進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告介紹的全球 PD-1 抑制劑藥物市場參與者的屬性。

目錄

第1章：前言

第2章：假設與研究方法

第3章：執行摘要：全球市場

第4章：市場概覽

  • 介紹
  • 概述
  • 市場動態
  • 2020-2035年全球市場分析與預測

第5章：關鍵見解

  • 主要地區/國家的監管格局
  • 市場趨勢
  • 波特五力分析
  • PESTEL分析
  • 最終用戶的關鍵購買指標
  • 品牌和定價分析
  • 重要產業活動
  • 國家/地區流行病學

第6章：全球市場分析與預測：依藥物類型

  • 介紹與定義
  • 主要發現/進展
  • 2020 年至 2035 年藥品市場價值預測
    • 帕博利珠單抗
    • 納武單抗
    • 西米普利單抗
    • 達他利單抗
    • 其他
  • 不同藥物類型的市場吸引力

第7章：全球市場分析與預測：按適應症

  • 介紹與定義
  • 主要發現/進展
  • 2020 年至 2035 年各適應症市場價值預測
    • 黑色素瘤
    • 霍奇金淋巴瘤
    • 非小細胞肺癌
    • 腎癌
    • 頭頸癌
    • 胃癌
    • 其他
  • 市場吸引力（按適應症）

第8章：全球市場分析與預測：按配銷通路

  • 介紹與定義
  • 主要發現/進展
  • 2020-2035年配銷通路市場價值預測
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 配銷通路的市場吸引力

第9章：全球市場分析與預測：按地區

  • 主要發現
  • 各地區市場價值預測
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 各國家/地區市場吸引力

第10章：北美市場分析與預測

  • 美國
  • 加拿大

第 11 章：歐洲市場分析與預測

  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區

第12章：亞太市場分析與預測

  • 中國
  • 日本
  • 印度
  • 澳洲和紐西蘭
  • 亞太其他地區

第13章：拉丁美洲市場分析與預測

  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區

第 14 章：中東和非洲市場分析與預測

  • 海灣合作理事會國家
  • 南非
  • 中東和非洲其他地區

第 15 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 各公司市佔率分析（2024 年）
  • 公司簡介
    • Akeso Biopharma Co., Ltd.
    • Alphamab Oncology
    • Amgen Inc.
    • AstraZeneca
    • BeiGene LTD.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company.
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences, Inc.
    • GSK plc.
    • Innovent
    • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    • Merck & Co., Inc.
    • Eli Lilly and Company
    • Boehringer Ingelheim International GmbH.
    • Other prominent players
Product Code: TMRGL86486

PD-1 Inhibitor Drugs Market - Scope of Report

TMR's report on the global PD-1 inhibitor drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global PD-1 inhibitor drugs market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global PD-1 inhibitor drugs market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the PD-1 inhibitor drugs market.

Market Snapshot
Market Value in 2024US$ 41.4 Bn
Market Value in 2035US$ 201.5 Bn
CAGR15.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global PD-1 inhibitor drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global PD-1 inhibitor drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global PD-1 inhibitor drugs market.

The report delves into the competitive landscape of the global PD-1 inhibitor drugs market. Key players operating in the global PD-1 inhibitor drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global PD-1 inhibitor drugs market profiled in this report.

Key Questions Answered in Global PD-1 inhibitor drugs Market Report:

  • What is the sales/revenue generated by PD-1 inhibitor drugs across all regions during the forecast period?
  • What are the opportunities in the global PD-1 inhibitor drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

PD-1 Inhibitor Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global PD-1 inhibitor drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global PD-1 inhibitor drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global PD-1 inhibitor drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global PD-1 Inhibitor Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, 2020-2035
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Regulatory Landscape across Key Regions / Countries
  • 5.2. PD-1 Inhibitor Drugs Market Trends
  • 5.3. PORTER's Five Forces Analysis
  • 5.4. PESTEL Analysis
  • 5.5. Key Purchase Metrics for End-users
  • 5.6. Brand and Pricing Analysis
  • 5.7. Key Industry Events
  • 5.8. Epidemiology by Country/Region

6. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Drug Type, 2020-2035
    • 6.3.1. Pembrolizumab
    • 6.3.2. Nivolumab
    • 6.3.3. Cemiplimab
    • 6.3.4. Dostarlimab
    • 6.3.5. Others
  • 6.4. Market Attractiveness By Drug Type

7. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Indication, 2020-2035
    • 7.3.1. Melanoma
    • 7.3.2. Hodgkin Lymphoma
    • 7.3.3. Non-Small Cell Lung Cancer
    • 7.3.4. Kidney Cancer
    • 7.3.5. Head and Neck Cancers
    • 7.3.6. Stomach Cancer
    • 7.3.7. Others
  • 7.4. Market Attractiveness By Indication

8. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Distribution Channel, 2020-2035
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness By Distribution Channel

9. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast By Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness By Country/Region

10. North America PD-1 Inhibitor Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Drug Type, 2020-2035
    • 10.2.1. Pembrolizumab
    • 10.2.2. Nivolumab
    • 10.2.3. Cemiplimab
    • 10.2.4. Dostarlimab
    • 10.2.5. Others
  • 10.3. Market Value Forecast By Indication, 2020-2035
    • 10.3.1. Melanoma
    • 10.3.2. Hodgkin Lymphoma
    • 10.3.3. Non-Small Cell Lung Cancer
    • 10.3.4. Kidney Cancer
    • 10.3.5. Head and Neck Cancers
    • 10.3.6. Stomach Cancer
    • 10.3.7. Others
  • 10.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast By Country, 2020-2035
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Type
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe PD-1 Inhibitor Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Drug Type, 2020-2035
    • 11.2.1. Pembrolizumab
    • 11.2.2. Nivolumab
    • 11.2.3. Cemiplimab
    • 11.2.4. Dostarlimab
    • 11.2.5. Others
  • 11.3. Market Value Forecast By Indication, 2020-2035
    • 11.3.1. Melanoma
    • 11.3.2. Hodgkin Lymphoma
    • 11.3.3. Non-Small Cell Lung Cancer
    • 11.3.4. Kidney Cancer
    • 11.3.5. Head and Neck Cancers
    • 11.3.6. Stomach Cancer
    • 11.3.7. Others
  • 11.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Type
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific PD-1 Inhibitor Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Drug Type, 2020-2035
    • 12.2.1. Pembrolizumab
    • 12.2.2. Nivolumab
    • 12.2.3. Cemiplimab
    • 12.2.4. Dostarlimab
    • 12.2.5. Others
  • 12.3. Market Value Forecast By Indication, 2020-2035
    • 12.3.1. Melanoma
    • 12.3.2. Hodgkin Lymphoma
    • 12.3.3. Non-Small Cell Lung Cancer
    • 12.3.4. Kidney Cancer
    • 12.3.5. Head and Neck Cancers
    • 12.3.6. Stomach Cancer
    • 12.3.7. Others
  • 12.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Type
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America PD-1 Inhibitor Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Type, 2020-2035
    • 13.2.1. Pembrolizumab
    • 13.2.2. Nivolumab
    • 13.2.3. Cemiplimab
    • 13.2.4. Dostarlimab
    • 13.2.5. Others
  • 13.3. Market Value Forecast By Indication, 2020-2035
    • 13.3.1. Melanoma
    • 13.3.2. Hodgkin Lymphoma
    • 13.3.3. Non-Small Cell Lung Cancer
    • 13.3.4. Kidney Cancer
    • 13.3.5. Head and Neck Cancers
    • 13.3.6. Stomach Cancer
    • 13.3.7. Others
  • 13.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Type
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa PD-1 Inhibitor Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Drug Type, 2020-2035
    • 14.2.1. Pembrolizumab
    • 14.2.2. Nivolumab
    • 14.2.3. Cemiplimab
    • 14.2.4. Dostarlimab
    • 14.2.5. Others
  • 14.3. Market Value Forecast By Indication, 2020-2035
    • 14.3.1. Melanoma
    • 14.3.2. Hodgkin Lymphoma
    • 14.3.3. Non-Small Cell Lung Cancer
    • 14.3.4. Kidney Cancer
    • 14.3.5. Head and Neck Cancers
    • 14.3.6. Stomach Cancer
    • 14.3.7. Others
  • 14.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Type
    • 14.6.2. By Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2024)
  • 15.3. Company Profiles
    • 15.3.1. Akeso Biopharma Co., Ltd.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Development
    • 15.3.2. Alphamab Oncology
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Development
    • 15.3.3. Amgen Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Development
    • 15.3.4. AstraZeneca
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Development
    • 15.3.5. BeiGene LTD.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Development
    • 15.3.6. Bristol-Myers Squibb Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Development
    • 15.3.7. Eli Lilly and Company.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Development
    • 15.3.8. F. Hoffmann-La Roche Ltd
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Development
    • 15.3.9. Gilead Sciences, Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Development
    • 15.3.10. GSK plc.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Business Strategies
      • 15.3.10.5. Recent Development
    • 15.3.11. Innovent
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Product Portfolio
      • 15.3.11.4. Business Strategies
      • 15.3.11.5. Recent Development
    • 15.3.12. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Financial Overview
      • 15.3.12.3. Product Portfolio
      • 15.3.12.4. Business Strategies
      • 15.3.12.5. Recent Development
    • 15.3.13. Merck & Co., Inc.
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Financial Overview
      • 15.3.13.3. Product Portfolio
      • 15.3.13.4. Business Strategies
      • 15.3.13.5. Recent Development
    • 15.3.14. Eli Lilly and Company
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Financial Overview
      • 15.3.14.3. Product Portfolio
      • 15.3.14.4. Business Strategies
      • 15.3.14.5. Recent Development
    • 15.3.15. Boehringer Ingelheim International GmbH.
      • 15.3.15.1. Company Overview
      • 15.3.15.2. Financial Overview
      • 15.3.15.3. Product Portfolio
      • 15.3.15.4. Business Strategies
      • 15.3.15.5. Recent Development
    • 15.3.16. Other prominent players
      • 15.3.16.1. Company Overview
      • 15.3.16.2. Financial Overview
      • 15.3.16.3. Product Portfolio
      • 15.3.16.4. Business Strategies
      • 15.3.16.5. Recent Development

List of Tables

  • Table 01: Global PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 02: Global PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
  • Table 03: Global PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
  • Table 04: Global PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, By Region, 2020-2035
  • Table 05: North America - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 06: North America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 07: North America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
  • Table 08: North America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
  • Table 09: Europe - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 10: Europe PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 11: Europe PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
  • Table 12: Europe PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
  • Table 13: Asia Pacific - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 14: Asia Pacific PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 15: Asia Pacific PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
  • Table 16: Asia Pacific PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
  • Table 17: Latin America - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 18: Latin America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 19: Latin America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
  • Table 20: Latin America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
  • Table 21: Middle East & Africa - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
  • Table 22: Middle East & Africa PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 23: Middle East & Africa PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
  • Table 24: Middle East & Africa PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035

List of Figures

  • Figure 01: Global PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
  • Figure 02: Global PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 03: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Pembrolizumab, 2020-2035
  • Figure 04: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Nivolumab, 2020-2035
  • Figure 05: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Cemiplimab, 2020-2035
  • Figure 06: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Dostarlimab, 2020-2037
  • Figure 07: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Others, 2020-2038
  • Figure 08: Global PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
  • Figure 09: Global PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
  • Figure 10: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Melanoma, 2020-2035
  • Figure 11: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Hodgkin Lymphoma, 2020-2035
  • Figure 12: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Non-Small Cell Lung Cancer, 2020-2035
  • Figure 13: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Kidney Cancer, 2020-2035
  • Figure 14: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Stomach Cancer, 2020-2035
  • Figure 15: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Others, 2020-2035
  • Figure 16: Global PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 17: Global PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 18: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Hospital Pharmacies, 2020-2035
  • Figure 19: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Retail Pharmacies, 2020-2035
  • Figure 20: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Online Pharmacies, 2020-2035
  • Figure 21: Global PD-1 Inhibitor Drugs Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 22: Global PD-1 Inhibitor Drugs Market Attractiveness Analysis, By Region, 2024-2034
  • Figure 23: North America - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 24: North America - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 25: North America - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 26: North America PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
  • Figure 27: North America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 28: North America PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
  • Figure 29: North America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
  • Figure 30: North America PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 31: North America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 32: Europe - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 33: Europe - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 34: Europe - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 35: Europe PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
  • Figure 36: Europe PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 37: Europe PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
  • Figure 38: Europe PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
  • Figure 39: Europe PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 40: Europe PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 41: Asia Pacific - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 42: Asia Pacific - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 43: Asia Pacific - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 44: Asia Pacific PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
  • Figure 45: Asia Pacific PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 46: Asia Pacific PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
  • Figure 47: Asia Pacific PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
  • Figure 48: Asia Pacific PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 49: Asia Pacific PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 50: Latin America - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 51: Latin America - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 52: Latin America - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 53: Latin America PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
  • Figure 54: Latin America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 55: Latin America PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
  • Figure 56: Latin America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
  • Figure 57: Latin America PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 58: Latin America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
  • Figure 59: Middle East & Africa - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 60: Middle East & Africa - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 61: Middle East & Africa - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 62: Middle East & Africa PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
  • Figure 63: Middle East & Africa PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
  • Figure 64: Middle East & Africa PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
  • Figure 65: Middle East & Africa PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
  • Figure 66: Middle East & Africa PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
  • Figure 67: Middle East & Africa PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035